Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
House dust mite allergen Der p 1 is a major glycoprotein allergen derived from the mid-gut and fecal pellets of the mite *Dermatophagoides pteronyssinus*. It is a papain-like cysteine protease and is present in both native and recombinant forms. Der p 1 exhibits structural homology and cross-reactivity with similar allergens such as Der f 1. Exposure to Der p 1 occurs via inhalation of mite excrement, and it can trigger robust IgE responses in sensitized individuals, causing allergic diseases such as asthma and allergic rhinitis. Mechanistically, Der p 1 disrupts airway epithelial barrier function by protease activity, leading to epithelial cell desquamation and facilitating allergen penetration. It induces the release of proinflammatory cytokines (e.g., IL-6 and IL-8) through proteinase-activated receptors. It also modulates immune responses by cleavage of immune cell surface receptors (CD23, CD25), promoting IgE production, and inactivates innate lung defense proteins such as elastase inhibitors. Der p 1 is routinely measured to diagnose genuine house dust mite allergy and guide allergen immunotherapy[1][2][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on house dust mite allergen der p1.